search
Back to results

Symptom-related Screening for Early Detection of CTEPH.

Primary Purpose

CTEPH, Pulmonary Embolism, Symptoms and Signs

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
dyspnea grade ≥ II according NYHA-WHO
Sponsored by
Luis Jara-Palomares, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for CTEPH focused on measuring CTEPH, Pulmonary Embolism, Symptoms and Signs, Dyspnea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age > 18 year
  2. Objectively confirmed diagnosis of acute PE by multidetector CT, V/Q lung scan, or selective pulmonary angiography, according to established diagnostic criteria, with or without symptomatic DVT,
  3. Ability of subject to understand the character and consequences of the study,
  4. informed consent of the subject.

Exclusion Criteria:

  • refused informed consent, inability to cooperation.

Sites / Locations

  • Hospital Universitario Puerto Real
  • Consorcio Hospitalario Provincial de Castellón
  • Hospital de Galdakao
  • Hospital General Universitario de Albacete
  • Hospital Universitario de Bellvitge
  • Parc Sanitari Sant Joan de Deu
  • Hospital Virgen de la Luz
  • Hospital Universitario Reina Sofía
  • Hospital General Universitario de Elche
  • Hospital Universitari de Girona Dr. Josep Trueta
  • Hospital Universitari Arnau de Vilanova
  • Hospital Clínico San Carlos
  • Hospital Universitario 12 de Octubre
  • Hospital Virgen del Rocio
  • Hospital Universitario Joan XXIII de Tarragona
  • Hospital Clínico Universitario Lozano Blesa

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Screening

Arm Description

Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities. In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines. In all patients, the following tests will be performed: Pulsioximetry. Electrocardiogram. Blood sample with determination of NT-ProBNP. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan. Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis

Outcomes

Primary Outcome Measures

Number of new diagnosis of CTEPH
New diagnosis of CTEPH

Secondary Outcome Measures

External validation from score to identify patients at risk to develop CTEPH
external validation from score (Klok FA et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2016)
Derivation of a score to identify high risk population to develop CTEPH
With variables assocciated to CTEPH investigators will obtain derivation and validation of a score to identify high risk population to develop CTEPH
Number of patients with Chronic Thromboembolic Disease (CTED) after PE
Describe the number and clinical characteristics of patients with CTED after PE

Full Information

First Posted
May 14, 2019
Last Updated
March 16, 2022
Sponsor
Luis Jara-Palomares, MD
Collaborators
Merck Sharp & Dohme LLC, Sociedad Española de Neumología y Cirugía Torácica
search

1. Study Identification

Unique Protocol Identification Number
NCT03953560
Brief Title
Symptom-related Screening for Early Detection of CTEPH.
Official Title
Symptom-related Screening Program Following Pulmonary Embolism for Early Detection of Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
January 16, 2019 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
February 15, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Luis Jara-Palomares, MD
Collaborators
Merck Sharp & Dohme LLC, Sociedad Española de Neumología y Cirugía Torácica

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Routine screening for Chronic thromboembolic pulmonary hypertension (CTEPH) i after PE is not supported by current evidence and guidelines. This study aims to evaluate if a screening program for patients with acute PE based on telephone monitoring of symptoms and further examination if only symptomatic patients could help an early detection of CTEPH.
Detailed Description
Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term complication following an acute or silent pulmonary embolism (PE). A history of acute PE was reported in 75% of CTEPH patients. Nevertheless, incidence of CTEPH after a confirmed acute PE vary widely depending of the studies, with estimated incidence from 0.5 to 4%. Performing a follow-up examination of patients diagnosed with acute PE regardless of persisting symptoms and using all available technical procedures is not cost-effective. As a consequence, routine screening for CTEPH after PE is not supported by current evidence and guidelines. CTEPH is a very disabling and mortal disease, although it is a potential curable disease. However, delayed diagnosis and misdiagnosis is common. Patients are frequently diagnosed with CTEPH at advanced stages of the disease leading to worse clinical outcomes. Early diagnosis of CTEPH is essential, as delay in diagnosis may be associated with a worse prognosis, higher perioperative mortality and inoperable diseases stages. Overall, evidence from various sources suggests that early detection and treatment of CTEPH is advantageous in achieving favorable clinical outcomes. Therefore, there is an important unmet need for early diagnosing this disease. Focusing diagnostic procedures only on symptomatic patients may be a practical approach for detecting relevant CTEPH. This study aims to evaluate if a screening program for patients with acute PE based on telephone monitoring of symptoms and further examination if only symptomatic patients could help an early detection of CTEPH. Objectives Primary outcome: To estimate the impact of an easy and simple strategy to identify CTEPH. Secondary outcomes: To identify patients with CTED after PE To obtain external validation from scores to identify patients at risk to develop CTEPH To develop new score to identify high risk population to develop CTEPH Hypothesis Conceptual hypothesis: The use of a strategy to detect CTEPH will increase number of patients diagnosed of pulmonary hypertension. Operational hypothesis: The use of a strategy to detect CTEPH will increase in a 200% the number of patients diagnosed with CTEPH. Design Cohorts study in consecutive patients with objectively confirmed PE. Specialists implied Internal medicine, Pulmonologist, Hematologist from 20 hospitals. Inclusion criteria: 1) Age > 18 year 2) Objectively confirmed diagnosis of acute PE by multidetector CT, V/Q lung scan, or selective pulmonary angiography, according to established diagnostic criteria, with or without symptomatic DVT, 3) Ability of subject to understand the character and consequences of the study, 4) informed consent of the subject. Exclusion criteria: refused informed consent, inability to cooperation. Intervention Investigator from each center will recover consecutive PE patients and collect baseline, demographic and co-morbidities. In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO modified scale will be cited as outpatient to be evaluated A written informed consent will be required all patients evaluated in consultant. Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines. In all patients, the following tests will be performed: Pulsioximetry. Electrocardiogram. Blood sample with determination of NT-ProBNP. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan. Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis The relationship of Doppler echocardiography-estimated PASP with right heart catheterization (RHC)-measured PASP was examined using Spearman's correlation coefficients. The Bland-Altman method was then used to assess the agreement between Doppler echocardiography-estimated and RHC measured PASP. Doppler echocardiography-estimated PASP within +/- 10mmHg of the value measured on RHC was considered accurate, consistent with the cutoffs used in other publications. Secondary outcome include number of patients with chronic thromboembolic disease (CTED), described as chronic thromboembolic pulmonary vascular obstruction with normal resting pulmonary artery pressures. Treatment: No treatment required Statistical Plans Sample size calculation We estimate CTEPH prevalence in reference group of 1%, and a prevalence of CTEPH in interventional group of 2.8%. With unilateral test, con confidence level of 95%, statistic power of 80% and losses expected of 25%, we calculated a final sample size of 947. The investigators calculate that 16-20 centers in Spain are needed to recruit patients Investigators will compare baseline characteristics of patients with and without CTEPH using chi-square tests for categorical variables and non-parametric rank tests for continuous variables. Cumulative incidence of CTEPH will be estimated using the Kaplan-Meier technique. To do external validation of previous score to predict CTEPH discriminative power by calculating the area under the receiver-operating characteristic (ROC) curve will be done, performing a non-parametric test of the equality of the areas under the ROC curves. Goodness-of-fit of the score points for each score in a logistic regression model using Pearson's chi-square test. Student's t test and X2 test (or Fisher's exact test where appropriate) will be used to compare continuous or categorical variables, and multivariable analysis through a logistic regression model using the Wald method (step back) to identify independent predictors for the occurrence of CTEPH. Covariates entering in the model will be selected by a significance level of p <0.20 on univariable analysis, or by a well-known association reported in the literature. Then, the investigators will build a prognostic score assigning points to each independent variable according to regression coefficients β, rounding to the nearest integer. The investigators will assign a risk score to each patient by adding up points for each independent variable. Performance will be quantified in terms of calibration using the Hosmer-Lemeshow test. Model discrimination will be assessed using the C-statistic. Internal validity of the score will be confirmed using bootstrap analysis. For the statistical analysis the investigators will use the IBM SPSS Statistics program (version 19; SPSS Inc., Chicago, IL), and a two-sided p<0.05 was considered to be statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
CTEPH, Pulmonary Embolism, Symptoms and Signs, Dyspnea
Keywords
CTEPH, Pulmonary Embolism, Symptoms and Signs, Dyspnea

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Design Cohorts study in consecutive patients with objectively confirmed PE.
Masking
None (Open Label)
Allocation
N/A
Enrollment
646 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Screening
Arm Type
Experimental
Arm Description
Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities. In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines. In all patients, the following tests will be performed: Pulsioximetry. Electrocardiogram. Blood sample with determination of NT-ProBNP. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan. Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis
Intervention Type
Diagnostic Test
Intervention Name(s)
dyspnea grade ≥ II according NYHA-WHO
Intervention Description
Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities. In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines. In all patients, the following tests will be performed: Pulsioximetry. Electrocardiogram. Blood sample with determination of NT-ProBNP. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan. Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis
Primary Outcome Measure Information:
Title
Number of new diagnosis of CTEPH
Description
New diagnosis of CTEPH
Time Frame
Up 3 years after PE
Secondary Outcome Measure Information:
Title
External validation from score to identify patients at risk to develop CTEPH
Description
external validation from score (Klok FA et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2016)
Time Frame
Up 3 years after PE
Title
Derivation of a score to identify high risk population to develop CTEPH
Description
With variables assocciated to CTEPH investigators will obtain derivation and validation of a score to identify high risk population to develop CTEPH
Time Frame
Up 3 years after PE
Title
Number of patients with Chronic Thromboembolic Disease (CTED) after PE
Description
Describe the number and clinical characteristics of patients with CTED after PE
Time Frame
Up 3 years after PE

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 year Objectively confirmed diagnosis of acute PE by multidetector CT, V/Q lung scan, or selective pulmonary angiography, according to established diagnostic criteria, with or without symptomatic DVT, Ability of subject to understand the character and consequences of the study, informed consent of the subject. Exclusion Criteria: refused informed consent, inability to cooperation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luis Jara-Palomares, MD
Organizational Affiliation
Medical Surgical Unit of Respiratory Diseases, Virgen del Rocio Hospital, CIBERES
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Universitario Puerto Real
City
Puerto Real
State/Province
Cadiz
Country
Spain
Facility Name
Consorcio Hospitalario Provincial de Castellón
City
Castellón De La Plana
State/Province
Castellon
Country
Spain
Facility Name
Hospital de Galdakao
City
Galdakao
State/Province
Vizcaya
Country
Spain
Facility Name
Hospital General Universitario de Albacete
City
Albacete
Country
Spain
Facility Name
Hospital Universitario de Bellvitge
City
Barcelona
Country
Spain
Facility Name
Parc Sanitari Sant Joan de Deu
City
Barcelona
Country
Spain
Facility Name
Hospital Virgen de la Luz
City
Cuenca
Country
Spain
Facility Name
Hospital Universitario Reina Sofía
City
Córdoba
Country
Spain
Facility Name
Hospital General Universitario de Elche
City
Elche
Country
Spain
Facility Name
Hospital Universitari de Girona Dr. Josep Trueta
City
Gerona
Country
Spain
Facility Name
Hospital Universitari Arnau de Vilanova
City
Lerida
Country
Spain
Facility Name
Hospital Clínico San Carlos
City
Madrid
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
Country
Spain
Facility Name
Hospital Virgen del Rocio
City
Sevilla
ZIP/Postal Code
41014
Country
Spain
Facility Name
Hospital Universitario Joan XXIII de Tarragona
City
Tarragona
Country
Spain
Facility Name
Hospital Clínico Universitario Lozano Blesa
City
Zaragoza
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Data will be included in RIETE registry. We will done all analyses prestablished and data collected could be used by RIETE investigators

Learn more about this trial

Symptom-related Screening for Early Detection of CTEPH.

We'll reach out to this number within 24 hrs